Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roche Holding AG's revenue per share for the
six
months ended in Dec. 2025 was CHF39.24.
Roche Holding AG's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF78.90.
Warning Sign:
Roche Holding AG revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Roche Holding AG was 1.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -1.10% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 2.60% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 3.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Roche Holding AG's Revenue per Share or its related term are showing as below:
XSWX:RO'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.3 Med: 3.2 Max: 15.5
Current: -1.1
During the past 13 years, Roche Holding AG's highest 3-Year average Revenue Per Share Growth Rate was 15.50% per year. The lowest was -2.30% per year. And the median was 3.20% per year.
XSWX:RO's 3-Year Revenue Growth Rate is ranked worse than 63.75% of 902
companies
in the Drug Manufacturers industry
Industry Median: 3.8
vs XSWX:RO: -1.10
Roche Holding AG (XSWX:RO) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Roche Holding AG Revenue per Share Related Terms
Roche Holding AG Revenue per Share Historical Data
* Premium members only.
The historical data trend for Roche Holding AG's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RO vs LLY, JNJ, ABBV: Revenue per Share Comparison
For the Drug Manufacturers - General subindustry, Roche Holding AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roche Holding AG PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Roche Holding AG's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Roche Holding AG's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF78.90
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roche Holding AG (XSWX:RO) has a Revenue per Share of CHF78.90 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Roche Holding AG and its competitors. According to the industry distribution chart, Roche Holding AG ranks #575 out of 902 companies in the Drug Manufacturers industry, placing it in the top 63.7%.
Is Roche Holding AG's Revenue per Share too high?
Roche Holding AG's current Revenue per Share is CHF78.90. Based on the distribution chart, Roche Holding AG ranks #575 out of 902 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Roche Holding AG has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's Revenue per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Roche Holding AG ranks #575 out of 902 companies for Revenue per Share. This places Roche Holding AG in the lower half of its industry. The industry median Revenue per Share is 3.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Drug Manufacturers company?
The median Revenue per Share among Drug Manufacturers companies is 3.80, based on 902 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Roche Holding AG and its competitors. For the Drug Manufacturers industry, the median Revenue per Share is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roche Holding AG's current Revenue per Share is CHF78.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF268.89, compared to a current price of CHF355.40 — trading 32.2% above its estimated fair value. The current Revenue per Share is CHF78.90. Roche Holding AG's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current Revenue per Share is CHF78.90 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roche Holding AG (XSWX:RO) Overvalued in 2026?
Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued.
The current stock price of CHF355.40 is trading 32.2% above its estimated GF Value™ of CHF268.89.
GuruFocus considers Roche Holding AG to be Significantly Overvalued.
Key valuation signals for XSWX:RO:
Revenue per Share: CHF78.90
GF Value™: CHF268.89 vs. price of CHF355.40 (32.2% above fair value)
No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
75GF Score
Get the complete analysis for XSWX:RO
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RO has been successfully added to your 
